And that onetime leprosy drug? It had been Revlimid, a best-selling cancer drug that, with annual sales of $8.2 billion, made up nearly two-thirds of Celgeneâe™s net sales in 2017. ", "type": "text"}, ("additions": [ {"URL": "https://youtu.be/K4AqlkL£s5w", "range" : ("len gth": 34, "start":174), "type":"link